Abstract
The aim of the present study was to analyze the differences in laboratory results between patients with severe and moderate coronavirus disease 2019 (COVID-19) for clinical intervention. The laboratory results of patients with COVID-19 between December 2019 and May 2020 were assembled from the Medline, Embase and Cochrane Library databases. A meta-analysis was conducted, calculating the individual and pooled odds ratios (ORs) with relative 95% confidence intervals (95% CIs) using Review Manager 5.3. The available data of 1,534 patients from 6 studies were included in this analysis. The results demonstrated that the incidence of leukocytosis, lymphocytopenia, increased procalcitonin (PCT), C-reactive protein (CRP), aspartate aminotransferase (AST) and lactic dehydrogenase (LDH) levels was associated with a nearly 3-fold (OR=3.44; 95% CI: 2.15-5.49), 4-fold (OR=4.39; 95% CI: 1.82-10.60), 5-fold (OR=5.28; 95% CI: 3.42-8.15), 4-fold (OR=3.99; 95% CI: 2.61-6.12), 3-fold (OR=3.02; 95% CI: 2.13-4.26) and 8-fold (OR=8.33; 95% CI: 1.75-39.69) higher risk of severe COVID-19 infection, respectively. These findings indicated that serial white blood cell count, lymphocyte count, CRP, PCT, LDH and AST measurements may be useful for predicting progression towards a more severe form of COVID-19.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
